INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $644,747 | +8.6% | 48,008 | 0.0% | 0.02% | +50.0% |
| Q4 2022 | $593,859 | -53.6% | 48,008 | -47.7% | 0.01% | -54.5% |
| Q3 2022 | $1,281,000 | +381.6% | 91,832 | +461.7% | 0.02% | +340.0% |
| Q1 2022 | $266,000 | 0.0% | 16,350 | 0.0% | 0.01% | -28.6% |
| Q4 2021 | $266,000 | -72.1% | 16,350 | -74.5% | 0.01% | -58.8% |
| Q3 2021 | $952,000 | -0.1% | 64,079 | +34.3% | 0.02% | 0.0% |
| Q2 2021 | $953,000 | – | 47,729 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |